It was reported via journal article that patient complications occurred.The study consisted of patients with hepatocellular carcinoma (hcc) patients with cholangiocarcinoma or combined hepatocarcinoma-cholangiocarcinoma were excluded.The inclusion started at august 2006 and finished at may 2016.The follow-up ended in november 2020.Patients underwent pretreatment assessment, including clinical history, physical examination, and laboratory and baseline imaging studies.The decision to treat patients with y90 as part of this study was made by consensus at weekly multidisciplinary hcc conference composed of staff from hepatology, medical oncology, hepatobiliary and transplant surgery, and diagnostic and interventional radiology.The procedure was conducted according to experts recommendation revised elsewhere.Patients were discharged from the hospital 24 hours after the procedure unless unexpected complications.Three patients experimented treated-related complications: actinic cholecystitis (n=1), transient liver decompensation (n=1) and celiac trunk dissection (n=1).No treatment-related deaths were registered.
|